Profile of mRNA Expression of IL-6 and IL-10 in Breast Cancer Patients with or Without Chemotherapy
American Journal of Clinical and Experimental Medicine
Volume 3, Issue 3, May 2015, Pages: 99-104
Received: Mar. 31, 2015; Accepted: Apr. 25, 2015; Published: May 11, 2015
Views 4417      Downloads 193
Authors
Victor Pontoh, Department of Surgery, Kandou Hospital of Medical Faculty, Sam Ratulangi University, Manado, Indonesia
Daniel Sampepajung, Department of Surgical Oncology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Andi Asadul Islam, Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Mochammad Hatta, Molecular Biology and Immunology Laboratory, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Article Tools
Follow on us
Abstract
ackground: Breast cancer is a type of cancer that has a high prevalence, can occur in men and women. Cytokines are factors that are known to have good properties of tumor growth and tumor inhibitory effects. Cytokine has an important role in the control of the immune system. Development of breast carcinoma is closely related to mRNA expression of IL-6 as pro-inflammatory cytokine and mRNA expression of IL-10 as anti-inflammatory cytokine. Purpose: Examine changes in mRNA expression of proinflammatory cytokine and anti-inflammatory cytokine in breast cancer patients with or without chemotherapy. Method: This is a case-control study, 12 subjects with breast cancer with chemotherapy as case group and 12 subjects with breast cancer without chemotherapy as control group. In this study we using PCR and RFLP techniques to detect polymorphisms in IL-6 and IL-10 gene. Results: In RFLP analysis, found that IL-6 and IL-10 gene were not polymorphic in all subjects for both case and control groups. Mean value of IL-6 mRNA on breast cancer patients without receiving chemotheraphy was 10.84±0.48 whereas on breast cancer patients with chemotherapy was 6.28±1.19. Mean value of IL-10 mRNA on breast cancer patients without receiving chemotheraphy was 6.76±0.81 whereas on breast cancer patients with chemotherapy was 9.81±1.07. The mean value of IL-6 mRNA on breast cancer patients without receiving chemotheraphy was statistically significant higher than in patients with chemotheraphy. In contrast, mean value of IL-10 mRNA on breast cancer patients without receiving chemotheraphy was statistically significant lower than in patients with chemotherapy. Conclusion: Combination of chemotherapy docetaxel, adriamycin, cyclophosphamide cause a decrease in mRNA expression of IL-6 and an increase in the expression of mRNA of IL-10 in patients with breast cancer.
Keywords
Breast Cancer, Chemotherapy, mRNA IL-6, IL-10
To cite this article
Victor Pontoh, Daniel Sampepajung, Andi Asadul Islam, Mochammad Hatta, Profile of mRNA Expression of IL-6 and IL-10 in Breast Cancer Patients with or Without Chemotherapy, American Journal of Clinical and Experimental Medicine. Vol. 3, No. 3, 2015, pp. 99-104. doi: 10.11648/j.ajcem.20150303.15
References
[1]
Danny R. Youlden, Susanna M. Cramb, Cheng Harip, Baade P: Incidence and mortality of female breast cancer in the Asia-Pacific region,. Brisbane 4000, Australia.; 2014.
[2]
Quan L, Gong Z, Yao S, Bandera EV, Zirpoli G, Hwang H, Roberts M, Ciupak G, Davis W, Sucheston L et al: Cytokine and cytokine receptor genes of the adaptive immune response are differentially associated with breast cancer risk in American women of African and European ancestry. International journal of cancer Journal international du cancer 2014, 134(6):1408-1421.
[3]
Balasubramanian SP, Azmy IA, Higham SE, Wilson AG, Cross SS, Cox A, Brown NJ, Reed MW: Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. BMC cancer 2006, 6:188.
[4]
Hamidullah, Changkija B, Konwar R: Role of interleukin-10 in breast cancer. Breast cancer research and treatment 2012, 133(1):11-21.
[5]
Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ: Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Roczniki Akademii Medycznej w Bialymstoku 2003, 48:82-84.
[6]
Dossus L, Kaaks R, Canzian F, Albanes D, Berndt SI, Boeing H, Buring J, Chanock SJ, Clavel-Chapelon F, Feigelson HS et al: PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis 2010, 31(3):455-461.
[7]
Reed MJ, Coldham NG, Patel SR, Ghilchik MW, James VH: Interleukin-1 and interleukin-6 in breast cyst fluid: their role in regulating aromatase activity in breast cancer cells. The Journal of endocrinology 1992, 132(3):R5-8.
[8]
Kundu N, Beaty TL, Jackson MJ, Fulton AM: Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. Journal of the National Cancer Institute 1996, 88(8):536-541.
[9]
Kong F, Liu J, Liu Y, Song B, Wang H, Liu W: Association of interleukin-10 gene polymorphisms with breast cancer in a Chinese population. Journal of experimental & clinical cancer research : CR 2010, 29:72.
[10]
Woo SU, Bae JW, Yang JH, Kim JH, Nam SJ, Shin YK: Overexpression of interleukin-10 in sentinel lymph node with breast cancer. Annals of surgical oncology 2007, 14(11):3268-3273.
[11]
Merendino RA, Gangemi S, Misefari A, Arena A, Capozza AB, Chillemi S, D'Ambrosio FP: Interleukin-12 and interleukin-10 production by mononuclear phagocytic cells from breast cancer patients. Immunology letters 1999, 68(2-3):355-358.
[12]
Boom R SC, Salimans MM, Jansen CL, Wertheim-van DillenPM, van der Noordaa J,: Rapid and simple method forpurification of nucleic acids. J ClinMicrobiol 1990, 29(496–503).
[13]
Camil L. Bohiltea, Radoi. VE: Interleukin-6 and interleukin-10 gene polymorphisms and recurrent pregnancy loss in Romanian population. Iran J Reprod Med 2014, 12(9):617–622.
[14]
Annapaula Giulietti, Lut Overbergh, Dirk Valck, Brigitte Decallonne, Roger Bouillon, Mathieu C: An Overview of Real-Time Quantitative PCR: Applications to Quantify Cytokine Gene Expression. . Methods 2001, 25:386–401.
[15]
Yajima T, Atsuhito Yagihashi, Daisuke Furuya, Kameshim H: Quantitative reverse transcription-PCR assay of the RNA component of human telomerase using the TaqMan fluorogenic detection system. Clinical chemistry 1998, 44(12):2441–2445.
[16]
Markkula A, Simonsson M, Ingvar C, Rose C, Jernstrom H: IL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohort. BMC cancer 2014, 14:759.
[17]
Cherel M, Campion L, Bezieau S, Campone M, Charrier J, Gaschet J, Ricolleau G, Gouraud W, Charbonnel C, Jezequel P: Molecular screening of interleukin-6 gene promoter and influence of -174G/C polymorphism on breast cancer. Cytokine 2009, 47(3):214-223.
[18]
Dai ZJ, Wang XJ, Zhao Y, Ma XB, Kang HF, Min WL, Lin S, Yang PT, Liu XX: Effects of interleukin-10 polymorphisms (rs1800896, rs1800871, and rs1800872) on breast cancer risk: evidence from an updated meta-analysis. Genetic testing and molecular biomarkers 2014, 18(6):439-445.
[19]
Giordani L, Bruzzi P, Lasalandra C, Quaranta M, Schittulli F, Della Ragione F, Iolascon A: Association of breast cancer and polymorphisms of interleukin-10 and tumor necrosis factor-alpha genes. Clinical chemistry 2003, 49(10):1664-1667.
[20]
Yu KD, Chen AX, Yang C, Fan L, Huang AJ, Shao ZM: The associations between two polymorphisms in the interleukin-10 gene promoter and breast cancer risk. Breast cancer research and treatment 2012, 131(1):27-31.
[21]
Lis CG, Grutsch JF, Vashi PG, CA. L: Is serum albumin an independent predictor of survival in patients with breast cancer? J Parenter Enteral Nutr 2003, 27:10-15
[22]
Cho YA, Sung MK, Yeon JY, Ro J, Kim J: Prognostic role of interleukin-6, interleukin-8, and leptin levels according to breast cancer subtype. Cancer research and treatment : official journal of Korean Cancer Association 2013, 45(3):210-219.
[23]
Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campas C, Dang L et al: Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clinical cancer research: an official journal of the American Association for Cancer Research 2006, 12(18): 5578-5586.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186